“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program, conditionally active cLAG3-IL2”
News Archive
How to Get the Biopharma Deal You Want
Business development (BD) is an essential ingredient to the success of early-stage companies, whether they plan to exit through M&A, IPO, or have other mechanisms to return money to investors. The most effective corporate strategies, while typically and necessarily focused on scientific goals, also closely integrate well designed BD objectives and scenarios. When the science […]
Bonum Therapeutics to Present Lead Program at AACR
“We are excited with the progress of our lead program, cLAG3-IL2, and are eager to make the first public presentation about the program at AACR.”
NextGen Class of 2024: Top Life Sciences Startups to Watch This Year
BioSpace is proud to present its NextGen Bio Class of 2024, a list of the hottest new life sciences companies in the United States. To come up with this list, BioSpace identified companies that launched between September 2022 and September 2023 with Series A funding. They were then assessed using several different criteria including finance, partnerships, pipeline, […]
IL-2 Program with Bonum’s Drs. John Mulligan and Neela Patel
On this week’s episode of the Business of Biotech, we welcome two extraordinary guests – Dr. Neela Patel, a molecular biologist-turned-Chief Business Officer, and Dr. John Mulligan, an academic-turned-founder of newly-formed Bonum Therapeutics. Together, Neela and John will pull back the curtain on Bonum’s transition from its predecessor, Good Therapeutics, which was fueled by a […]
From Good to Great: Unlocking a biopharma platform’s full potential
Good Therapeutics, founded in 2016 by molecular biologist John Mulligan, Ph.D., was acquired by Roche in 2022 for $250 million upfront plus potential milestone payments. Even better, Mulligan and company retained their platform and the ability to mine it for innovative drugs to fight cancer and other diseases. The potential for conditionally active protein technology […]
A BD Checklist: Best Practices for Partnering with Pharma
Throughout my 25+ years in industry, whether I am advising startups or mentoring individuals interested in career transitions to business development, I am often asked about my approach to deal making. Here I share some best practices for biotechs looking to partner an asset with pharma. I still use this approach to make better decisions […]
Realizing the Therapeutic Potential of Cytokines by Making them Context Dependent
Cytokines, which play an essential role in immune cell signaling, have long been recognized as having great therapeutic potential, but efforts to harness them have been hampered by their toxicity. Bonum Therapeutics is overcoming this limitation by engineering cytokines with a sensor domain that makes their activity dependent on their environment. While the company is […]
Should My Biotech Startup Buy Or Produce The Proteins We Use?
I joined Good Therapeutics (now Bonum Therapeutics) in the summer of 2021. This was a marvelous opportunity to develop a new class of regulated cytokine therapeutics for cancer and autoimmune diseases. My prime directive was to build a team focused on protein production and characterization, with an aim to select stable “manufacturable” leads to move […]